Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 6/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.34 |
| ▸ | TP53 | P04637 | 4/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3827361 | 1.00 | CACNA1H (0.36) | CACNA1HMDM2TP53OPRK1MAPK8 | |
| SCHEMBL13567914 | 0.85 | CACNA1H (0.35) | CACNA1HMDM2TP53OPRK1 | |
| SCHEMBL3832262 | 0.83 | MDM2 (0.42) | MDM2TP53HCAR3HCAR2 | |
| SCHEMBL3832265 | 0.83 | MDM2 (0.42) | MDM2TP53HCAR3HCAR2 | |
| SCHEMBL3833362 | 0.81 | MEN1 (0.39) | MDM2TP53MAPK1ELANE | |
| SCHEMBL3833365 | 0.81 | MEN1 (0.39) | MDM2TP53MAPK1ELANE | |
| SCHEMBL3830291 | 0.76 | TP53 (0.36) | MDM2TP53MAPK1ELANE | |
| SCHEMBL3830287 | 0.76 | TP53 (0.36) | MDM2TP53MAPK1ELANE | |
| SCHEMBL3834249 | 0.76 | HSD11B1 (0.53) | MDM2TP53 | |
| SCHEMBL3834250 | 0.76 | HSD11B1 (0.53) | MDM2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | CACNA1H 4530/4885MDM2 2/4885TP53 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.